S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Mar

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors

BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma

Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance

Can Viral Respiratory Infections Increase Lung Cancer Risk